Intellia’s gene editing breakthrough is historic
Head of Equity Strategy
Summary: Intellia Therapeutics' share price rose 50% yesterday as the biotechnology company showed promising results against a rare genetic liver disease. The gene editing technology is one of the most promising technology within disease treatments and the key to unlock the full potential of adaptive cell therapies.
Back in January we launched our NextGen Medicine theme basket consisting of 30 companies within what we call the frontier of biotechnology. There is the mature biotechnology industry, which is closer to the old pharmaceutical industry, and then there is this new frontier of biotechnology companies working antibody therapies, gene editing, T-cell therapy, immunology, mRNA technology and genetic diagnostics.
Over the weekend, Intellia Therapeutics and Regeneron Pharmaceuticals (part of the mature biotechnology industry) released a landmark phase 1 clinical data showing significant reduction in disease-causing protein following CRISPR therapy for Transthyretin (ATTR) Amyloidosis. Experts have called this a major breakthrough for the promising gene editing technology CRISPR, pioneered by the two female scientists Charpentier and Doudna which won them the Nobel Prize in Chemistry, which is necessary to increase the potential of adoptive cell therapy (ACT). The news lifted Intellia’s share price by 50% yesterday and our NextGen Medicine basket by 3.9% showing how Intellia’s result is lifting the outlook for many of these new emerging biotechnology companies within these new technologies.
The table below shows the 30 companies in our NextGen Medicine basket and provide a broad-based exposure to this part of the biotechnology industry. It is our expectation that the biggest breakthroughs in medicine over the coming decades will come from this part of industry. Some of the other gene editing companies in the list are CRISPR Therapeutics, Beam Therapeutics, Editas Medicine and PTC Therapeutics.
|Name||Domicile||Mkt cap in USD mn||R&D in %||12M Rev in USD mn||Burn rate||Insti %|
|Exact Sciences Corp||US||22,475||2.8||1,546||NM||102.3|
|CRISPR Therapeutics AG (**)||CH||11,489||2.6||1||5.5||70.5|
|Mirati Therapeutics Inc||US||8,861||3.7||13||4.2||114.9|
|Fate Therapeutics Inc||US||8,380||1.5||40||10.2||110.2|
|Ultragenyx Pharmaceutical Inc||US||6,505||6.9||334||2.9||132.2|
|Twist Bioscience Corp||US||6,177||0.8||113||2.5||126.1|
|Denali Therapeutics Inc||US||9,095||2.4||340||NM||102.1|
|Arrowhead Pharmaceuticals Inc||US||8,974||1.8||89||NM||74.1|
|Iovance Biotherapeutics Inc||US||4,116||4.9||0||2.4||127.3|
|Pacific Biosciences of California Inc||US||7,010||1.0||92||4.0||91.8|
|Beam Therapeutics Inc||US||6,812||4.0||0||2.3||106.8|
|Swedish Orphan Biovitrum AB||SE||5,533||3.5||1,612||NM||107.9|
|Sage Therapeutics Inc||US||3,345||8.6||1,113||NM||119.8|
|Intellia Therapeutics Inc||US||9,094||1.7||52||8.7||109.3|
|Editas Medicine Inc||US||2,988||5.5||92||2.2||87.1|
|PTC Therapeutics Inc||US||3,067||17.0||430||4.8||124.2|
|Allogene Therapeutics Inc||US||3,616||5.7||38||4.5||125.7|
Source: Bloomberg and Saxo Group
Table explanations: R&D in % is the 12-month R&D expense in % of market cap, Burn rate is the number of years the company can sustain current negative free cash flow (NM means not measurable and is used for those with positive free cash flow), Insti % is the institutional ownership of the floating shares (those that are tradeable, so if all shares are not publicly available then the ratio can be above 100%) in %.
** Peter Garnry has holdings in these companies
Latest Market Insights
Q4 Outlook 2022: Winter is coming
- Winter is coming to the financial markets as central banks are tightening their grip. How spring will look is still a question.
European energy crisis: it will get worse before it gets betterThe winter in Europe will be tough, but whether the result is political chaos or sustainable, innovative solutions is still undecided.
A difficult and volatile quarter awaitsAs the year draws to an end, commodities continue to be at centre stage of the world with growth pockets political uncertainty.
The bright side: crises drive innovationThe positive spin on crises is that they come with solutions. It is worrisome that deglobalisation may be a response to this crisis.
Green transformation in China: renewable energy and beyondGoing green, China needs to span numerous energy sources to ensure stability, as every source comes with a challenge.
Asia: Intermittent solutions, but a faster renewable adoption curveAsian energy supply is being squeezed. This and the adoption of renewables may change the investment sentiment in the region.
FX: A Fed thaw needed to deliver a sustained USD turn lowerThe US Dollar can keep momentum when the Federal Reserve continues to tighten, leaving the rest to play to their drum.
Autumn can become ugly for equities and bond holders. Comfort for Dollar longsTechnical analysis suggests that equities could face a tough Q4 as could fixed income. US Dollar positions could provide some upside.
The next stock market sector to watch, with stocks going nuclearAs the world scrambles to find affordable, sustainable energy, nuclear is getting attention from politicians and investors alike.
The crypto space is getting cold when the hype disappearsCryptocurrencies face a winter of their own as retail investors and governments are asking tough questions.